Pan-Indian study finds that higher levels of DNA fragments in blood strengthen cancer signals
You donβt have any Active Subscription.
Account subscription benefits alongside Premium Stories, Editorials, Opinions and more. Unlock these with Subscription
The study examined how DNA released by different cells in the body influences the detection of cancer. | Image for representational purposes only | Photo Credit: Bevan Goldswain
A blood test that looks for cancer-related changes in DNA has shown the potential to detect multiple types of cancer. In a study, the test detected 72% of cancer cases, with a false-positive rate of 1.4%.
The blood test, CancerSpot, developed by Bengaluru-based Strand Life Sciences, uses DNA sequencing and Artificial Intelligence (AI) to identify changes in DNA that can indicate the presence of cancer. The research, involving 1,480 participants and 43 hospitals across India, including five in Karnataka, was conducted over four years as part of the development and clinical validation of the test. The findings have been published in the Proceedings of the National Academy of Sciences (PNAS), a peer-reviewed scientific journal.
Cells in the body release small fragments of DNA into the bloodstream. These are known as circulating or cell-free DNA. In people with cancer, some of these fragments originate from tumour cells and carry changes that can help identify the disease.
CancerSpot combines DNA sequencing with AI-based analysis to examine patterns of DNA methylation. Methylation refers to chemical modifications of DNA that influence how genes function. These patterns differ between cancer cells and normal cells and can be used to identify cancer-associated signals in a blood sample.
By analysing these patterns, the test aims to detect multiple types of cancer through a single blood test, without requiring a tissue biopsy for the initial detection, said Ramesh Hariharan, CEO of Strand Life Sciences, who is one of the authors of the study.
The study examined how DNA released by different cells in the body influences the detection of cancer. An important finding was that higher levels of circulating DNA were associated with stronger cancer-related signals and better detection sensitivity, even among patients at the same stage of cancer.
Researchers had expected that the increased release of DNA from immune cells in cancer patients would dilute the tumour-derived DNA signals, making cancer detection more difficult. However, the study found the opposite.
The findings suggest that DNA released by tumour cells and immune cells increases together in cancer patients, helping strengthen the cancer-related signals in the blood. This provides new insights into the interaction between tumours and the immune system and its role in blood-based cancer detection, explained Mr. Hariharan, who is also an Adjunct Professor at the Indian Institute of Science, Bengaluru.
CancerSpot was evaluated in newly diagnosed patients with 14 types of cancer and healthy individuals. In an independent validation cohort, it detected 72% of patients with cancer, with a false-positive rate of 1.4%.
A low false-positive rate is important in cancer screening, as it can help reduce unnecessary follow-up investigations and invasive procedures among healthy individuals.
Mr. Hariharan said the challenge in early cancer detection was to maximise the number of cancers detected while minimising false positives that could lead to unnecessary medical procedures.
Sewanti Limaye, director of Medical and Precision Oncology at Sir H.N. Reliance Foundation Hospital and a co-author of the study, said the findings challenged an existing assumption in liquid biopsy research. She said further independent validation would be needed to translate the discovery into screening strategies that improve early diagnosis and patient outcomes.
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.

